|
Seventh European Medicines Agency - Medicines for Europe annual bilateral meeting
|
|
1
|
101
|
August 27, 2024
|
|
Analytical methodologies to detect N-nitrosamine impurities in active pharmaceutical ingredients, drug products and other matrices -Pub
|
|
0
|
250
|
August 27, 2024
|
|
🇧🇷 Guideline for the control of Nitrosamines Rev. 4
|
|
24
|
1509
|
August 21, 2024
|
|
AI for NDSRI by Brazil regulatory
|
|
6
|
835
|
August 7, 2024
|
|
South African Health Products Regulatory Authority (Nitrosamines)
|
|
2
|
690
|
August 5, 2024
|
|
👨💻 Dashboard Containing Published AI Limits
|
|
32
|
3569
|
August 2, 2024
|
|
🇲🇽 Coming July Mexico Nitrosamines Guideline
|
|
5
|
468
|
August 2, 2024
|
|
Extension of the implementation deadline for "Self-inspection on Risks of Contamination with Nitrosamines in Drug" in Japan
|
|
2
|
175
|
July 30, 2024
|
|
The clinical and regulatory status of NDSRI: A global imperative -Pub
|
|
1
|
246
|
July 30, 2024
|
|
EMA/CHMP Concept paper on the revision of the guideline on the chemistry of active substances
|
|
4
|
592
|
July 29, 2024
|
|
Swissmedic updated requirements for dealing with potential nitrosamine impurities in medicinal products
|
|
2
|
514
|
February 1, 2024
|
|
Development and Manufacture of Oligonucleotides + Nitrosamines
|
|
0
|
266
|
July 24, 2024
|
|
🇪🇺 EMA/409815/2020 Rev.21 (19-Jul-24)
|
|
1
|
1822
|
July 22, 2024
|
|
ICH M7 plans to harmonize AI limits for Nitrosamines
|
|
1
|
297
|
June 13, 2024
|
|
Nitrosamines in food raise a health concern (EFSA)
|
|
7
|
1069
|
June 11, 2024
|
|
Update: EFPIA workflows for Quality Risk management Jun 2024 v03
|
|
2
|
754
|
June 4, 2024
|
|
🇰🇷 Case study on the Occurrence of Impurities in Pharmaceuticals (Focusing on NDMA Cases)
|
|
0
|
299
|
May 31, 2024
|
|
Justify the presence of amine in the API chemical structure
|
|
3
|
266
|
May 29, 2024
|
|
FDA releases FY23 GDUFA Science and Research Report
|
|
0
|
270
|
May 24, 2024
|
|
🇪🇺 EDQM - top 10 deficiencies observed in new CEP applications
|
|
0
|
930
|
March 14, 2024
|
|
An Organic Guide to N-Nitrosamines: Structure, Reactivity, and Role as Contaminants
|
|
1
|
511
|
May 13, 2024
|
|
APIC NA Risk Assessment Template
|
|
5
|
3277
|
May 11, 2024
|
|
🇪🇺 EDQM - Certification of suitability to Monographs of the European Pharmacopoeia
|
|
1
|
563
|
April 12, 2024
|
|
EMA - Update Appendix 3: Enhanced Ames Test conditions for N-nitrosamines
|
|
8
|
1711
|
April 2, 2024
|
|
USP-NF General Notices Revision open for Comments
|
|
0
|
1140
|
March 7, 2024
|
|
Updated: IPEC Position Paper on Role of Excipients in Determining N-Nitrosamine Risks for Drug Products
|
|
3
|
1112
|
March 7, 2024
|
|
CDER Drug Safety Priorities Fiscal Year 2023
|
|
1
|
584
|
February 16, 2024
|
|
New ICH Guideline Q14
|
|
0
|
488
|
February 12, 2024
|
|
Nitrosamine requirements for probiotics
|
|
4
|
356
|
February 12, 2024
|
|
Top 10 deficiencies observed in new CEP applications for chemical purity assessed in 2023
|
|
1
|
636
|
February 9, 2024
|